Pyrazine derivatives as modulators of tyrosine kinases
申请人:——
公开号:US20030060629A1
公开(公告)日:2003-03-27
The present invention provides pyrazine derivatives that inhibit tyrosine kinase activity. Certain pyrazine derivatives are selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The present invention also provides pharmaceutical formulations containing the pyrazine derivatives and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.
v. Braun; Blessing; Zobel, Chemische Berichte, 1924, vol. 57, p. 187
作者:v. Braun、Blessing、Zobel
DOI:——
日期:——
PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES
申请人:Ortho-McNeil Pharmaceutical, Inc.
公开号:EP1330452A2
公开(公告)日:2003-07-30
US6710048B2
申请人:——
公开号:US6710048B2
公开(公告)日:2004-03-23
[EN] PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES<br/>[FR] DERIVES DE PYRAZINE TENANT LIEU DE MODULATEURS DE TYROSINE KINASE
申请人:ORTHO MCNEIL PHARM INC
公开号:WO2002024681A2
公开(公告)日:2002-03-28
The present invention provides pyrazine derivatives that inhibit tyrosine kinase activity. Certain pyrazine derivatives are selective inhibitors of vascular endothelial growth factor (VEGF) receptor tyrosine kinase. The present invention also provides pharmaceutical formulations containing the pyrazine derivatives and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis.